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A B S T R A C T
Background and aim: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease; the clinical
manifestations are correlated with continuum multiarticular synovitis, cartilage and bone damage, and defeat of
joint function, that causes disability. Involvement of internal organs is also frequent. Between the inflammatory
cells involved in RA, macrophages play a key role. These cells can polarize in different phenotype and mediate
https://doi.org/10.1016/j.autrev.2019.102397
Received 28 April 2019; Accepted 3 May 2019
Abbreviations: RA, Rheumatoid Arthritis; M1, classically activated macrophages; M2, alternatively activate anti-inflammatory macrophages; AP, Cs, antigen pre-
senting cells; TNF-α, tumoral necrosis factor- alpha; IL, interleukin; TGF-β, transforming growth factor- beta; PRISMA, Preferred Reporting Items for Systematic
reviews and Meta-Analyses; WOS, Web of Science; SD, Science Direct; PB, peripheral blood; FACS, fluorescence-activated cell sorting; CD, Cluster Differentiation; HD,
healthy donors; JIA, Juvenile Idiopathic Arthritis; SJIA, systemic-JIA; IFN-γ, interferon-gamma; MDM, Monocytes derived macrophages; GM-CSF, Granulocyte/
Monocytes-Colony Stimulation Factor; M-CSF, Macrophages-Colony Stimulation Factor; MFI, mean fluorescence intensity; OC, osteoclast; OA, osteoarthritis; MΦ,
polarized macrophages; FR-β, Folate Receptor beta; iNOS, inducible nitric oxide synthetase; PHD3, prolyl hydroxylase 3; CCR, C-C motif chemokine receptor; MMP,
matrix metalloproteinase; EGLN3, egl nine homolog 3; INHBA, inhibin subunit beta A; CypA, Cyclophilin-A; NF-kB, nuclear factor kappa-light-chain-enhancer of
activated B cells; TSPO, translocator protein; LPS, lipopolysaccharide; SIRT, Sirtuin; AMPK, adenosine monophosphate-activated protein kinase; RSV, Resveratrol;
MDC, macrophage-derived chemokine; FcεRII, Fc epsilon RII; MrC1, C-type mannose receptor 1; SEMA3A, Semaphorin 3A; DAS28, Disease Activity Score 28; RF,
Rheumatoid Factor; PBMC, peripheral blood mononuclear cells; BMM, Bone Marrow Macrophages; ROS, reactive oxygen species; ARG1, arginase1; Fizz1, found in
inflammatory zone 1; Ym1, mouse chitinase-like 3; μRNA, micro-Ribonucleic Acid; CCL, (C-C motif) chemokine ligand; ACPAs, Anti-citrullinated protein antibodies;
ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; TLRs, Toll Like-Receptors; IRF, contain two proteins involved in Toll Like-Receptors (TLRs) signaling,
namely Interferon; bDMARDs, biological disease-modifying antirheumatic drugs; MerTK, Tyrosine protein kinase Mer; SOCS3, Suppressors of cytokine signaling 3;
Gas6, MerTK ligand; pSTAT3, phospho Signal Transducer and activator of transcription; Pam3, Pam3CysSerLys4; FOLR2, FR-β 2; SLC40A1, solute carrier family 40
member 1; HMOX1, heme oxygenase 1; STIA, sterile arthritis; IVIG, intravenous gamma-globulin; AIA, antigen-induced arthritis; FcγRI, Fc gamma receptor I; IL-1RII,
(IL)-1 receptor II; SIO, steroid induced osteonecrosis; CIA, collagen induce arthritis; IL-10−/−, IL-10 null mice; IRF5−/−, (IRF)-5 null mice; Tg, transgenic; WT, wild
type; 11β-HSD, 11 beta-hydroxysteroid dehydrogenase; GCs, glucocorticoids; Tg197, mouse model that express stabilized human TNF-α; KO, knock out; CSF1, colony
stimulating factor 1; Hes1-GFP, Drosophila hairy and enhancer of split 1 plus green fluorescence protein; CH3, C3H/HeNCrl; B6, C57BL/6NCr; Bbaa1, Borrelia
burgdorferi–associated locus 1; IFN, interferon; MFC-MSNS, Manganese ferrite and ceria nanoparticle-anchored mesoporous silica; ML-WA, Withaferin-A in-
corporated in mannosylated liposomes; Pae, paeoniflorin; CP-25, Paeoniflorin-6′-O-benzene sulfonate; AA, adjuvant induced arthritis; MTX, Methotrexate; AP,
alkaline phosphatase; sSiglec-9, sialic acid-binding immunoglobulin-type lectin; p65, NF-kb subunit/cofactor proto-oncogene RelA; FUTs, fucosyltransferases; 2-D-
gal, fucose/galactose analog; siRNA, silencing RNA; CB2, Cannabinoid Receptor 2; JWH133, 3-(1′1′Dimethylbutyl)-1-deoxy-D8-tetrahydrocannabinol CB2 agonist;
CXCR3, C-X-C motif chemokine receptor 3; JN2, (N-(4-(5-chlorobenzo[d]oxazol-2-ylamino)phenyl)−4-aminobutanamide) CXCR3 antagonist; CXCL, C-X-C motif
chemokine ligand; RANKL, TNF superfamily member 11; Tnfsf11, RANKL transcript; TCR, T cells receptor; KRN, mouse strain that stably express TCR; NOD, non-
adaptive immunologic function; SCID, severe combined immunodeficiency; IL2Rγ−/−, (IL)-2R gamma null; M0, unpolarized macrophages; DMSO, dimethyl sulf-
oxide; MHCII, major histocompatibility complex II; ON, osteonecrosis; FLS, Fibroblast like synovitis; ET-1, endothelin-1; ESR, erythrocyte sedimentation rate; ETA,
etanercept; ADA, adalimumab; CTLA4-Ig, Cytotoxic T-Lymphocyte Antigen 4- Immunoglobulin; IHC, immunohistochemical
⁎ Corresponding author at: Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, IT-16132 Genova, Italy.
E-mail addresses: tarditosamuele.hrd@gmail.com (S. Tardito), giulia.martinelli2@gmail.com (G. Martinelli), stefano.soldano@unige.it (S. Soldano),
sabrina.paolino@unige.it (S. Paolino), greta.pacini@gmail.com (G. Pacini), dr.massimo.patane@gmail.com (M. Patane), elisa.alessandri@yahoo.it (E. Alessandri),
vanessa.smith@ugent.be (V. Smith), mcutolo@unige.it (M. Cutolo).
1 Samuele Tardito and Giulia Martinelli contributed equally to this work.
Autoimmunity Reviews 18 (2019) 102397
Available online 11 September 2019
1568-9972/ © 2019 Published by Elsevier B.V.
T
the immune/inflammatory reaction as well as the reparatory phase when possible. The properties of these cells
are mediate by the body's environmental factors.
In this systematic review, all English-speaking articles concerning the role of M1 (pro-inflammatory) or M2
(anti-inflammatory) macrophages in RA were systematically reviewed and categorized according to their po-
larized-function in RA, especially in the synovial tissue. Analyses of the endogenous molecules and the drugs that
could modulate M1 and M2 activity in RA were achieved.
Methods: A sensitive search was developed in Pubmed, Web of Science, Ovid Med-Line, Embase Database and
Science Direct Database (la both from Elsevier) to identify articles to increase the highlighting on the role of
macrophages M1 and M2 in RA using the following terms: ((M1 AND M2) AND Rheumatoid Arthritis). All
selected papers were read and discussed by two independent reviewers. The selection process was based on title,
abstract and full text level. Relevant data were extracted and analyzed using a standardized template designed
for this review.
Results: In total 39 resulting articles were selected and categorized according to description of M1/M2's role in
RA. Data from humans, mice and rats were subcategorized, thus in every section were highlighted the con-
tribute, in peripheral blood and synovial tissue, of both polarized macrophages; section for endogenous mole-
cules and drugs that favor the switch from M1 to M2 macrophages were carried out. The most evinced relevant
results, were that in RA blood and in the synovial tissue, there isn't a clear distinction phase with M1 or M2
macrophages (by membrane marker analysis); rather there is M1 and M2 subset disequilibrium and by deeply
analyses of mRNA gene and cytokine produced, it emerged that a non-coherent expression inner marker match
with membrane molecules, and also the tissue section can define the marker expressed.
Conclusion: This systematic review emphasizes that the rigid classical subdivision of M1 and M2 macrophages,
as well as the different samples' results comparison, might be questionable. In addition, it is suggested, when
taking samples from RA patients, to carefully consider their therapies in order to analyze the M1 and M2
macrophages behavior without drug influence.
In line with the advances in M1 and M2 knowledge, and the progression in the single-cell methodologies by
identification of individual cell molecular markers, therapeutic approaches seem possible to favor the anti-
inflammatory macrophage response in RA (e.g. M2 polarization).
1. Introduction
Rheumatoid Arthritis (RA) is a chronic immune-mediated in-
flammatory disease that impacts almost 1% of the population world-
wide. It causes advanced joint damage and mainly affects the synovial
tissues, cartilage and bone [1]. Furthermore, the systemic and organ
complications of RA are associated with a high incidence of morbidity
and rising mortality [2,3]. Over the last fifty years, scientific con-
tribution has produced numerous concepts as to how immune responses
impact the RA disease [3].
This immune-mediated disorder involves, both innate and adaptive
cellular compartments as well as their dysregulated cytokine production,
moreover the cellular resident in the bone and in joint compartments,
such as osteoclast, chondrocyte and stromal cells are involved [4].
Within the innate immunity function that causes inflammation, macro-
phages have a key role. In fact, they contribute to the normal tissue
homeostasis, working as APCs to activate adaptive immunity [5,6], pa-
thogen expulsion, resolution of inflammation and wound healing.
In particular, the studies relating to the function of macrophages in
inflammation have progressed gradually and scientists have identified
two different polarization states [4,7].
Classically activated macrophages (M1), causes joint erosion, se-
creting principally proinflammatory cytokines such as TNF-α and IL-1
and alternatively activate macrophages (M2), which through a high
production of anti-inflammatory cytokines (mainly IL-10 and TGF-β)
contributes to vasculogenesis, tissue remodeling and repair, as recently
observed in systemic sclerosis. Markers for both phenotypes may co-
exists on the same cell as recently reported for the first time in systemic
sclerosis by our group [8,9].
The aim of this systematic review, using Med-Line and non-Med-
Line research, is to summarize the previously published data on M1/
M2's role in RA synovial tissue, as well as discussing selected mole-
cules/drugs in animal models and in RA patients that might modulate




A systematic search, in line with the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA [10]) guidelines, was
carried out on Pubmed, WOS, Ovid (Med-Line database), Embase and
SD (Elsevier Databases). It was performed without any limitation to the
publication date in order to identify articles focused on the role of M1
and M2 macrophages cellular compartments in the RA disease (eval-
uated in Humans, Mice, Rats) in particular, highlighting their role in
synovial tissue.
The Medical terms for RA were used in combination with M1 and
M2 (note that we used the “AND” Boolean Logic Symbol, to restrict the
area of investigation, as follow: M1 AND M2 AND Rheumatoid
Arthritis). The structured search was last updated on 3th May 2019.
2.2. Screening process
All articles were screened by two independent reviewers (ST and
GM). The reviewing selection process was based on title, abstract and
full-text level, using Covidence [11,12], a tool, produced in partnership
with Cochrane Reviews which simplify the systematic review process.
All studies, explaining the activities of M1 and M2 macrophages in the
pathogenesis of RA, were included in the systematic review with par-
ticular inclusion of articles which focused on synovial tissue.
All study designs, with the exception of reviews, editorials, case
studies and conference abstracts/posters, were included. Languages,
other than English, were excluded, as well as studies that were not
available in full-text version format. However, titles and abstracts se-
lected by either one of the reviewers were included for additional
screening. At each level of the screening process, where different opi-
nions existed among the ST and GM as to whether to include a record or
not, it should be noted that a mutual agreement was reached (see Fig. 1.
for the flowchart).
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In addition, all selected full-texts meeting the inclusion criteria were
once again, checked by ST and GM. In the same way, relevant data was
extracted and analyzed using a standardized template designed for this
review.
3. Results
Of the 2262 articles screened (by title, abstract and full-text level)
that were considered potentially relevant to the topic of this study, 39
articles were included. The flow of the searching and selection process
is shown in Fig. 1. Supplementary File 1 summarizes all 39 selected
manuscripts focused on M1 (classically-activated macrophages) and M2
(alternatively-activated macrophages) in RA. The 39 selected articles
(the detailed data are shown in Table 1) were categorized according to
the description of M1/M2's role in RA: the data corresponding to human
and rodents (i.e. mice and rats) have been considered as the two main
categories since they have an impact on M1/M2 cellular compartments.
Within these two groups, the records evaluated were those from mac-
rophage polarization contribution on inflammation or tissue repair,
endogenous molecules that are important in maintaining macrophages
homeostasis or that exacerbate the pro-inflammatory macrophages re-
sponse, together with exogenous molecules (drugs) that impact and can
modulate the M1/M2 reaction. All records considered macrophage ac-
tivity, especially in peripheral blood and synovial tissue.
3.1. Human
Macrophages play an important role in RA. Inflamed RA synovial
tissue and inflammatory vascular reactions both presented a higher
number of macrophages compared to healthy joints [13,14].
In inflammatory conditions, macrophages were found to be wide-
spread in the RA lining of the synovial tissue [15]. The circulating
monocytes represent the principal source of these cells. These PB
monocytes exist in three different populations which are grouped based
on their expression of cell-surface molecules and functions [16]. Phe-
notypical FACS analysis of PB classic CD14+CD16−, intermediate
CD142+CD16+ and non-classic CD14dimCD16+ monocytes reveal no
cellular membrane marker difference between RA patients and HD
[17].
Moreover, studies in Juvenile Idiopathic Arthritis (JIA) or Systemic-
JIA (SJIA), common forms of arthritis in children and adolescents,
confirmed that the distribution of the CD14+ and CD16+ sub-popula-
tions are not altered in comparison to HD [18].
3.1.1. M1 and M2 in peripheral blood from rheumatoid arthritis patients
Studies of both ex-vivo and in vitro PB monocyte markers, which
simulate the polarization of M1 or M2 macrophages, have been carried
out in the past few years.
CD14+ monocytes were purified from the PB of RA patients and
compared with the same cells from HD in order to evaluate if ex-vivo
and in vitro polarization markers of M1 and M2 macrophage cellular
compartments are already appreciable. Conversely, CD64 (MΦ-IFN-γ),
CD-200R (MΦ- IL-4) and CD-16 (MΦ-IL-10) labeling did not show a sig-
nificant difference between the two groups [17]. Monocytes-derived
macrophages (MDM) stimulated with GM-CSF or M-CSF in vitro, did
not show any particular difference in M1 or M2 marker expressions
(GM-CSF M1 macrophage express CD163 and CD206 which should be
M2 markers) and the same results were obtained from ex-vivo mono-
cytes analysis (evaluation of monocytes % and/or MFI) [19].
Confirmation of these results comes from another study where sci-
entists analyzed M1 (CD68+CD192+) and M2 (CX3CR1+CD163+),
and, once again, no significant difference was found, concluding that
RA PBs seem to be composed by mixed M1 and M2 monocyte sub-po-
pulations [19,20].
Likewise, in SJIA, PB surface phenotyping monocytes compared to
HD did not show any significant difference; spontaneous cytokine
production analysis confirmed the same result [18].
Nevertheless, a more in-depth analysis among M1 and M2 markers
under flare and quiescence conditions resulted in a more robust dif-
ference. In fact, CD14+ monocytes showed mixed M1/M2 at flare and
instead an antigen panel towards M2-like pic at quiescence. However,
CD16+ monocytes did not change their surface markers during flare or
quiescence and were seen to be more associated with M1-like marker
production.
Furthermore, Fukui et al. confirmed that the distribution of mono-
cyte sub-types, divided by CD14 and CD16 expression, showed no sig-
nificant differences between RA patients and HD. In addition, M1/M2
correlated in a significantly-positive manner with the OC number [21].
3.1.2. M1 and M2 from rheumatoid arthritis synovial tissue
Macrophages in inflamed synovial tissue are the cells which are
mainly activated in RA and are the principal source of cytokines, such
as TNF-α, which contribute to the disease progression. If indeed mac-
rophages play a pathogenic role in RA, as confirmed by numerous ex-
perimental data, the degree of joint erosion and the contribution to
hyperplasia of the intimal synovial lining layer could also be linked to
the increased number in the synovial tissue [22].
It should be noted that there is a macrophage subset disequilibrium
from RA patients' synovial fluid with the M1/M2 ratios being higher in
RA compared to OA patients [21,23]. In a double-immunofluorescence
staining study, the CD68+ marker has been colocalized with the fol-
lowing markers: of IFN-γ dependent polarization markers (MΦIFN-γ), of
IL-4 dependent polarized markers (MΦIL-4), of IL-10 dependent polar-
ized markers (MΦIL-10) [17,24].
Intimal lining layer was found to contain mainly mature resident
macrophages (the MΦIL-10 markers CD163 and CD32 colocalized with
CD68+), whereas the synovial sublining showed more mixed pheno-
types (CD68+ colocalized with MΦIL-10 markers CD163 and CD32 and
the MΦIFN-γ marker CD64, and the MΦIL-4 CD200R and CD14+), sug-
gesting that it is actively infiltrated with immature MDM. Moreover,
disease activity in RA seemed associated with the number of synovial
sublining macrophages, but not with intimal lining layer macrophages
[17]. In addition, CD163+ synovial-derived macrophages colocalize
with the FR-β and this expression depends on their distribution in sy-
novial sub-tissue.
In fact, FR-β is more expressed by CD163+ in the sublining layer of
the synovial tissue and these cells produce more iNOS, and more IL-10
Fig. 1. Data are given as number of selected articles categorized according to
four different parts of the search process: identification, screening, eligibility
and inclusion. The format of this figure is based on PRISMA 2009 guideline
[10].
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and TGF-β than the intimal lining layer, thus confirming the more
mixed phenotypes observed in the synovial sublining layer.
Conversely, the cells CD163+FR-β+ in both layers also produce
TNF-α [25].
Furthermore, from another study, similar observations were found.
In fact, the cells CD163+ M2 anti-inflammatory macrophages from
synovial tissue when tested for protein production and expressed high
levels of pro-inflammatory markers (PHD3, [CCR]-2, [MMP]-12 and
TNF-α) [22].
Lastly, CD14+ cells from RA synovial fluid express low levels of M2
anti-inflammatory markers, accordingly with a high level production of
pro-inflammatory genes ([CCR]-2, [MMP]-12, and EGLN3 INHBA)
[26,27]. Moreover, they possess high a pro-inflammatory polarization
ability (induced by proteins such as activin A, PHD3 and [MMP]-12)
[22].
3.1.3. Endogenous molecules that can modulate M1 and M2 polarization in
rheumatoid arthritis
Macrophages, together with other specific cells (i.e. T-cells, fibro-
blasts), are responsible for joint swelling in RA, which reflects synovial
tissue inflammation. While a balance between pro-inflammatory and
anti-inflammatory factors is a condition for normal synovial tissue ac-
tivities, in RA. On the contrary, an imbalance between producers and
inhibitors of the inflammatory reaction is evident. In fact, a complex
cytokine and chemokine network is involved in the inflammatory en-
vironment [28,29].
Among a total of eight articles it was found that different en-
dogenous molecules were reported and highlighted as essential med-
iators of inflammation or, more importantly, crucial for maintaining the
milieu homeostasis.
For example, the activity of CypA seems to induce pro-inflammatory
signaling pathways in many specific cells, among which also macro-
phages. A growing body of evidence has suggested its pathological role
in RA and many other human diseases [30].
CypA expression was detected in both RA and OA synovial tissue.
The absolute concentration of CypA in RA was much higher than that in
OA synovial tissues [31]. CypA induced the expression of cytokines/
chemokines, such as TNF-α, IL-8, MCP-1, IL-1β and (MMP)-9, through a
pathway that is eventually dependent on NF-kB activation [32]. The
macrophage marker TSPO is a mitochondrial membrane protein which
could be involved in a negative macrophage regulation during RA in-
flammation [33].
Moreover, MDM from synovial tissue showed a strong up-regulation
of TSPO compared to their monocyte counterparts. Conversely, this
expression was counterbalanced when synovial MDM were tested with
M1 stimuli (LPS or IFN-γ). Interestingly, at both mRNA and protein
level, TSPO showed a significant down-regulation by 24 h compared to
those cells stimulated with IL-4, TGF-β or Dexamethasone [33].
Sirtuin 1 (SIRT)-1 is a histone/protein deacetylase which works in
tandem with AMPK to control metabolism-transcriptional gene ex-
pression, neuroprotection, and inflammation. MDM from synovial
tissue when activated with Resveratrol (RSV a (SIRT)-1 activator) can
up-regulate the M2 transcripts (MDC, FcεRII, or CD23, MrC1, and IL-
10) and suppress the M1 macrophages markers [(CCL)-2, iNOS, and IL-
12 p40] [34].
The activity of (SIRT)-6 was found to be negatively correlated with
IL-6 concentration in RA patients, and it was hypothesized that its en-
zymatic activity was strictly connected to the inflammatory process.
Furthermore, SEMA3A, a membrane protein with an axonal prop-
erty, participates, among other activities, in bone homeostasis main-
tenance.
In fact, its concentration in RA synovial tissue seems significantly
lower than that compared to the OA samples, and it is negatively cor-
related with RA disease progression in serum (DAS28 and RF [35,36]).
The expression of SEMA3A in vitro, derived from BMM and under
polarization stimuli, seems to block the expression of the markers
(iNOS)-2, ROS, the cytokines IL-1β, IL-6 and TNFα and boosted the
increase of M2 mRNA specific markers expression Arg1, Fizz1, Ym1,
CD206, CD163). Eventually, SEMA3A was found to promote the switch
from M1 classically-activated macrophages to M2 alternatively-acti-
vated macrophages [37].
In fact, in synovial tissue, synovial fluid and PBMC-derived mono-
cytes from RA patients rather than from OA patients, the (SIRT)-6
protein levels were significantly decreased [38].
Moreover, in order to define a specific μRNA expression profile in
CD14+ purified monocytes obtained from the peripheral blood of 27
JIA patients, an analysis of 110 μRNA was performed.
The results showed that miR-125a-5p was found to be highly up-
regulated in vitro tests, and it drove the polarization of stimulated
macrophages to anti-inflammatory (M2) counterparts. As a major re-
sult, it was shown that miR-125a-5p drove the polarization towards
M2b and M2c sub-groups [39].
Comparable with this result, CD14+ monocytes from 32 children
with SJIA showed that the expression of miR-146a was increased and
was correlated with systemic features. In addition, transfection ex-
periments demonstrated that miR-146a is linked with the generation of
alternatively-activated M2 macrophages (inducing the increase of the
genes Arg1, (CCL)-17 and (CCL)-2 associated with the markers CD163
and CD206) [40].
Anti-citrullinated protein antibodies (ACPA) and auto-antibodies
are very important in the diagnosis of RA because they can also predict
disease severity [41]. The M1/M2 ratio imbalance seems to be asso-
ciated with the number of OCs in ACPAs+ RA Patients- Although
ACPAs, ESR and CRP were found to be correlated with a M1/M2 ratio,
the latter is the sole significant factor that contributes to the number of
OCs [21].
Cells isolated from RA patients' synovial fluid are a high source of
activin A, which promotes the production of GM-CSF-dependent po-
larization markers and inhibits the expression of M-CSF-dependent
markers in both monocytes and macrophages, thus supporting its pos-
sible contribution to the prevalent pro-inflammatory polarization of
macrophages (M1) in RA synovial tissues [22]. Synovial fluids from RA
patients also contain two proteins involved in TLRs signaling, namely
(IRF)-4 and (IRF)-5. ACPAs antibodies, purified from RA serum, seem to
induce a significant increase in the M1/M2 ratio in vitro, as well as
(IRF)-4 and (IRF)-5 at mRNA levels.
However, only (IRF)-5 from silencing experiments were found to be
associated with the action of ACPAs [23]. Interestingly, the study by
Kang et al. showed why IFN-γ drives the polarization of macrophages
towards the M1 state [42].
Notwithstanding this mechanism being helped by numerous mole-
cular processes [43,44], they found epigenomic evidence which shows
how IFN-γ repressed several genes by disassembling the regulatory
elements that control the gene expression (enhancers). Specifically,
IFN-γ, from RA synovial macrophages, suppressed M2-related homeo-
static and reparative genes binding the transcription factor called MAF,
thus de-activating the upstream gene enhancer [42].
3.1.4. Exogenous molecules (drugs) that can modulate M1 and M2
polarization in rheumatoid arthritis
The migration of CD68+ macrophages in the synovial tissue is a
biomarker of both disease severity and results of therapeutic activities
[45]. However, data relating to the consequences of RA bDMARDs on
macrophage polarization are very limited. Anti-cytokine bDMARDs
have been shown to decrease the inflammatory burden caused espe-
cially by recruited inflammatory monocytes/macrophages [46]. In fact,
only one study analyzed the effect of bDMARDs modulation of M1 and
M2 polarization [46].
Anti-TNF agents seem to provoke the modification in macrophage
polarization from inflammatory to anti-inflammatory status, meaning
the down-regulation of the surface markers M1-like, such as CD40 and
CD80, to the up-regulation of the surface marker M2-like, such as CD16,
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CD163 and MerTK. Additionally, anti-TNF agents prevent the produc-
tion of inflammatory cytokines (TNF-α, IL-6, IL-12) and increase the
phagocytosis of macrophages via the higher production of IL-10 which
controls the inflammatory process by the activation of Gas6 and SOCS3.
Noteworthy, IL-10 mediates the switch from M1 to M2 through
pSTAT3. The other bDMARDs that were studied did not induce any
polarization into macrophage subsets [46].
Lastly, the stimulation of fresh monocytes with Pam3 [19], a (TLR)-
2 agonist, did not significantly modify the classical surface marker
profile of M2 macrophages. Conversely, LPS, a (TLR)-4 agonist, is re-
sponsible for the low-level activation of M2 markers against the high-
level production of M1 markers (evaluated as MFI values). Likewise, the
action of Pam3 down-regulated the mRNA M2 marker (FRβ)-2 and
SLC40A1, but not HMOX1. The induction with LPS or LPS plus IFN-γ
seems to amplify all mRNA markers mentioned above. Surprisingly,
Pam3 induces a high production of pro-inflammatory cytokines (IL-1β,
IL-6, and IL-8) in M2 macrophages. Stimulation of M1 and M2 with
combination of Pam3 and LPS induces an up-regulation of (TLR)-2 and
a down-regulation of (TLR)-4 [19].
3.2. Mice and rats
Due to the complexity of RA, there is still a lack of understanding of
the fundamental causes of the disease. For example, the trigger to the
beginning of the articular disease is still unknown, and the molecules
that define chronicity versus resolution of inflammation are also poorly
understood. Therefore, the use of animal models remains essential in
order to delineate the molecular mechanisms of the disease so as to
develop novel therapies.
To date, various mouse models are available which involve different
immune cell types and which address distinct stages in the course of RA
[47,48].
3.2.1. M1 and M2 from blood and synovial tissue of RA models
The K/B×N serum-transfer mouse model for STIA summarizes the
onset phase of human RA, but it is independent on the adaptive immune
response. The model depends on the immune-complex engagement of
activating Fc receptors on macrophages, and IVIG preserve mice from
the disease through the expression of inhibitory Fc receptors [49]. The
work of Misharin et al. showed that non-classical Ly6C− monocytes
(that correspond to human CD14dimCD16+ monocytes) are required for
the induction and progression of sterile joint inflammation in the K/
B×N mice RA model [50].
Non-classical Ly6C− monocytes polarize into inflammatory macro-
phages (M1), induce disease pathogenesis and demonstrate plasticity
during the resolution phase [50].
Throughout the progression of arthritis, Ly6C− monocytes differ-
entiate towards an alternatively activated phenotype (M2), promoting
the joint inflammation resolution and all these steps occur without
changes in the synovial tissue-resident macrophages [50].
In order to better characterize the gene expression of AIA in in-
flamed mice synovial tissue, a microarray analysis was carried out [51].
The M1 markers (IL-1β, IL-6, FcγRI and CD86) were strongly up-
regulated during the course of AIA whereas the majority of M2 markers
([IL]-1RII, CD163, CD206, Arg1 and Ym1) were also somewhat up-
regulated, with the exclusion of Arg1 and Ym1 which were exclusively
and differentially expressed from the outset of AIA. In fact, this might
once again indicate a change towards an M1 signature in the inflamed
synovial tissue even during AIA [51].
Lastly, in the mouse model of SIO, a clinical condition simulating
late RA, M1 macrophages increased during the beginning phase to-
gether with an altered M1/M2 ratio, while the expression of TNF-α
remained high [52].
When the concentration of TNF-α decreased, and the tissue entered
a resolution phase also the macrophages were found to have mainly
shifted to the M2 anti-inflammatory state [52].
3.2.2. Endogenous molecules that can modulate M1 and M2 polarization in
RA models
In total, six studies of both ex-vivo and in vitro studies were found in
which different molecules drove PB and synovial monocytes/macro-
phages towards the polarization in M1 or M2 macrophages.
In the mouse model of (SIRT)-1-Tg CIA, a model very similar to
human RA progression, Park et al. confirmed the data obtained from
reported human experiments [34]. In this experiment, the (SIRT)-1
over-expressed mice were found to develop less severe arthritis than
WT C57BL/6 N mice; noteworthy, the (SIRT)-1 over-produced aug-
mented the release of M2 markers (i.e. arginase-1) and, decrease the
concentration of M1 markers (i.e. TNF-α and IL-1β) [34].
The 11 beta-hydroxysteroid dehydrogenase type 1 (11β-HSD) en-
zyme transforms GCs inactive to their active counterparts, conferring
tissue-specific increase and exposure to active endogenous and ther-
apeutic GCs [53].
As matter of fact, a Tg197 mouse model was cross-linked with
mouse line KO for 11β-HSD and it was found that they developed more
severe arthritis than WT C57BL/6 J-induced arthritis mice and showed
a larger infiltration of M1 macrophages in the synovial tissues. This
data confirms the increase of pro-inflammatory cytokines (IL-1, IL-6,
CSF1), and supports the anti-inflammatory properties of 11β-HSD [53].
Likewise, in a combination of in vitro cell cultures and a TNF-Tg
arthritic mice model, carrying an Hes1-GFP transgene as an indicator of
Notch activation, Sun et al. found that Notch signaling [54] has
strength connection with M1 macrophage polarization and its inhibi-
tion reduces joint tissue inflammation by inducing a change from M1 to
M2 macrophage [55].
Conversely, a mouse model depleted by IL-10 (IL-10−/−) worsened
CIA, and promoted macrophage polarization towards pro-inflammatory
M1, confirming that IL-10 production could maintain the homeostasis
between inflammatory and anti-inflammatory macrophages [56].
Moreover, a high amount of IL-10 provokes the switch from M1 to M2
macrophages [56].
In regards to the anti-inflammatory molecule, the study of Woo
et al. confirmed the results obtained in RA patients. In fact, in a mouse
model of (SIRT)-6 deficiency, CIA arthritis was induced and showed an
expanded CD68+ cell immunoreactivity in the intimal lining and sub-
lining synovial tissue. Moreover, M1 macrophages linked genes, che-
mokines, and receptors and proteases were increased [38].
In line with human data, Zhu et al. found a mouse model, knocked
out for (IRF)-5, produced a macrophage shift to its M2 anti-in-
flammatory counterparts [23]. In addition, they confirmed that IRF5−/
− mice were lower producers of pro-inflammatory cytokines, such as
TNF-α, IL-6, and IL-12.
Furthermore, the intracellular staining of macrophages in the mouse
model, knocked out for (IRF)-5, demonstrated that the transcription
factor was more present in M1 than in M2 macrophages.
In addition, an ex-vivo study of AIA mice confirmed that the (IRF)-5
protein was higher in M1 pro-inflammatory than M2 (CD206+) anti-
inflammatory macrophages in the affected knee. Moreover, CD206+
macrophages expressed more (IRF)-5 at the site of inflammation than
they did before the challenge [57,58].
We can also consider data from Lyme-arthritis studies which are
useful in extrapolating information about M1 and M2 macrophage be-
havior and indeed they might be comparable to RA studies. In fact, we
found one study where Lyme-arthritis was induced in C3H/HeNCrl
(CH3) and C57BL/6NCr (B6) mice infected by bacterial Borrelia burg-
dorferi–induced Lyme-arthritis [59]. In this study Ma et al. showed how
Bbaa1 modulated the macrophage polarization [59].
The Bbaa1 B6 allele stimulated the expression of the M2 markers,
whereas the Bbaa1 C3H allele promoted the typical production of M1
markers [59].
The studies eventually identified Bbaa1 as a regulator of type I IFN
response during both Lyme-arthritis and RA development. This finding
is consistent with the hypothesis that inherent patterns of gene
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expression, controlled by Bbaa1 alleles, may possibly direct the func-
tional phenotype of macrophages as classically (M1) ones versus al-
ternatively (M2) polarized ones [59].
3.2.3. Exogenous molecules that can modulate M1 and M2 polarization in
models of RA
It is possible that enhancements in the exploration of nanother-
apeutic techniques might provide new solutions to bypass the defects of
existing treatments. Therapeutic drugs can be selectively distributed to
and accumulated in the inflamed sites via the passive or active targeting
of nano-vehicles after systemic administration. This therapeutic method
has, in fact, reduced the damage to other organs and the “vehicle”
protects the drug until it reaches the burden site.
Eleven studies of therapeutic molecules that drive PB and synovial
monocytes/macrophages towards polarization in M1 or M2 macro-
phages were herein analyzed.
3.2.3.1. Rats. In AIA rats, manganese ferrite and ceria nanoparticle-
anchored mesoporous silica (MFC-MSNs) exhibit a synergistic effect on
O2 generation and ROS elimination, inducing a shift of M1 to M2
macrophage polarization both in vitro and in vivo [60].
In a rat model of induction of the AIA, a gene therapy, with IL-10
DNA plasmid encapsulated in nanoparticle carrying the protein tuftsin,
was constructed to reach effectively synovial tissue macrophages.
The IL-10 gene therapy nanoparticle protein driven, induced a
change of membrane polarization markers in synovial macrophage,
from M1 to M2. In addition, the treatment induced systemic reduction
of serum and synovial pro-inflammatory cytokines (TNF-α, IL-1β, and
IL-6) [61].
Moreover, targeted delivery of Withaferin-A incorporated in man-
nosylated liposomes (ML-WA) ameliorated the gravity of inflammation
in AIA rats, inducing the M1 to M2 macrophage polarization shift [62].
Instead Chang et al. have improved the bio-availability of monoterpene
glucoside Pae by producing one novel ester: CP-25. The paeoniflorin-6′-
O-benzene sulfonate (CP-25) have many beneficial activities in AIA
rats. In fact, it repressed the production of pro-inflammatory cytokines
(TNF-α, IL-1 and IL- 6), increasing the TGF-β1 concentration. The ef-
fects were similar to the effects of MTX alone. CP-25 treatment in-
hibited M1 macrophage production and increased M2 macrophage ac-
tivation by inducing cytokine release [63].
Finally, alkaline phosphatase (AP) administration in arthritic rats,
alone or in combination with MTX reduced the macrophages' infiltra-
tion level of CD68+ and CD163+ in the synovial tissue. The reduced
number of infiltrated CD68+ macrophage were statistically significant
compared to normal rats [64].
3.2.3.2. Mice. In mouse model of CIA, sSiglec-9 significantly
ameliorated the clinical and histological evidence and gravity of
arthritis. While sSiglec-9 diminished the expression of M1 markers
RelA/p65 in macrophages, it did not affect the expression of M2
markers [65].
Furthermore, the study of Li et al. [66], to obtain additional data in
function of FUTs in RA polarization of macrophages, were supported
with in vivo study in CIA mice. They found that there was a decrease in
the percentages of CD11b+Ly6C−, CD11b+TNF-α, and CD11b+IL-23+
M1 inflammatory macrophages in mice treated with fucose/galactose
analog 2-D-gal. The higher amount of this molecule has been implicated
in the shift M1 to M2 macrophage polarization state.
Instead, a micelle mixture, loaded with dexamethasone and siRNA
against the NF-kB-p65 transcription factor, effectively inhibited NF-kB
signaling in murine macrophages. The co-distribution method was ef-
ficient enough to switch macrophages from the M1 to the M2 state [67].
Furthermore, in order to better understand the role of CB2 on OC
formation and differentiation in inflammation-induced cartilage and
bone destruction, Zhu et al. tested JWH133, a selected agonist of CB2,
in a CIA murine model. JWH133 treatment diminished the infiltration
of pro-inflammatory M1-like macrophages in the knee joint and re-
polarized macrophages from the M1 to M2 phenotype [62]. The acti-
vation of CB2 increased the expression of anti-inflammatory cytokine
interleukin IL-10 and reduced the expression of pro-inflammatory cy-
tokines, including TNF-α, IL-1β, and IL-6 [68].
Lastly, from an antagonist of CXCR3 (JN-2) was evaluated the ef-
ficacy on the modulation of (CXCL)-9/10/11, on the progression of
arthritis in a CIA mouse model [69]. The results showed that the in-
creased levels of TNF-α, IL-6, and RANKL (one of M1 Macrophages
marker) were greatly inhibited. Additionally, the CIA-induced mRNA
expression of TNFα, IL-6, and RANKL transcript (Tnfsf11) were blocked
by JN-2-injected mice [69].
In the K/B × N serum transfer RA murine model (yielded from KRN
strain crosslinked with NOD-SCID IL2Rγ−/− strain) DMSO injection
produced a contradictory result. In fact, the forepaws, but not the hind
paws, expressed significantly lower levels of pro-inflammatory genes
(IL-1β, IL-6, CXCL1 and CXCL2) after DMSO treatment. Surprisingly, in
mice derived BMM DMSO acts to block the polarization of M0 macro-
phages into M1 or M2 phenotypes [70].
4. Discussion
In the present systematic review, detailed aspects of the activities
and polarization properties of M1 and M2 macrophages have been re-
viewed for the first time in RA blood, synovial tissue and synovial
fluids. The aim of the review is to give a comprehensive overview of the
current literature available, presenting the results obtained from find-
ings in humans, mice and rats, including endogenous or exogenous
molecules which participate in inducing the polarization of macrophage
(M1 or M2).
From the analysis of literature regarding RA models. it was revealed
that in mice blood there is a non-classical Ly6C− monocyte population
(human's CD14dimCD16+ monocytes) which are essential for the in-
itiation and progression of arthritis at the level of inflammatory reac-
tions. These cells, polarized in pro-inflammatory M1 macrophages,
provoke tissue inflammation and differentiate into anti-inflammatory
M2 macrophage cells to resolve the burning milieu [50].
Surprisingly, resident synovial macrophages do not change during
inflammation; moreover, they do not present the MHCII marker
(MHCII−CXCR3+), they populate the synovial tissue since the em-
bryonic development, and they have a key role in maintaining its
homeostasis [50].
On the other hand, Rossol et al. found that the intermediate
CD142+CD16+ human blood monocytes (corresponding to Ly6Cint in
mice) have a higher frequency in patients with RA than in HD, whereas
non-classical CD14dimCD16+ monocytes (corresponding to Ly6C− in
mice) are unchanged in RA [71].
Conversely, our findings in this systematic review analysis, using
human phenotypical analyses, on three specific blood monocyte po-
pulations (i.e. classic CD14+CD16−, intermediate CD142+CD16+ and
non-classical CD14dimCD16+) reveal that there are no differences be-
tween RA and HD subjects [17].
Moreover, CD14+ and CD16+ populations did not change in JIA
patients compared to HD subjects [18].
More detailed phenotypical and cytokine production analysis of PB
cells also revealed that blood from RA and JIA patients is composed of a
mixed M1 and M2 monocyte sub-population [17,18,20] while Cd14+
monocytes show the M2 phenotype in the quiescence phase [21].
Although RA blood monocytes and activated macrophages do not
show any differences compared to HD, our review reveals that there is a
more complex situation in synovial tissues. Since mono IHC analysis
reveals a subset marker disequilibrium (mixed M1/M2 markers) re-
sulting from double immunofluorescence, we can confirm that the sy-
novial tissue intimal lining layer shows more mature and defined
macrophages, and it would seem that this tissue region has already
started the resolution phase (CD68+ colocalizing with CD163+ and
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CD32+; CD163+ macrophages colocalizing with FR-β [25], but pro-
ducing much more IL-10 and TGF-β than TNF-α and iNOS) [17].
These findings were further endorsed by a ON mice study where
scientists found a correlation between TNF-α decreasing and the onset
of the resolution phase [52].
On the contrary, the sublining tissues show a much more mixed
phenotype (MΦIL-10/MΦIFN-γ mixed markers and cytokines) [17]. A
gene expression study from rodents, during the course of AIA, showed
that, although two M2 markers remained high and stable throughout
the disease period (Arg1 and Ym1), M1 markers were strongly up-
regulated (IL-1β, IL-6, FcγRI and CD86) [51].
Eventually, comprehensive analyses of RA synovial fluid macro-
phages focused, in particular, on cell membrane receptors, genes and
protein expressions, showed that in CD14+ lineage, anti-inflammatory
membrane markers were expressed at a low level while pro-in-
flammatory genes and proteins were produced at high levels [22].
However, contrary to this result, Palacios et al. also found that, from
synovial tissue, M2 macrophage lineage expressing CD163+ produces a
high amount of proinflammatory proteins [22]. Moreover, the local
inflammatory milieu in synovial fluid can block the expression of
CD200R and CD163 markers by M2 macrophages [72]. (See Fig. 2 for a
detailed illustration showing the distribution of macrophages in the
layers of synovial tissue).
Based on these results, any possible limitations related to such an
approach should be fully considered in order to understand the role of
M1 and M2 polarization in RA.
However, since our intention with this review was to give the most
complete overview possible of the literature on this somewhat difficult
topic, only analyzed studies in which more than five RA patients were
recruited have been included. However, the differences in the method
of the cohort sample choice from different laboratories, for example,
the definition of early/ active phase / remissive RA patients, or the
characterization of the differences found between the therapies, has not
allowed us to produce a meta-analysis of the data extracted from the
studies selected.
Nevertheless, standardization advances have been made in the past,
two examples being the studies from Bresnahan et al. and Smith et al.
which both proposed the setting method in IHC evaluation and in-
filtration of macrophages from synovial tissue [73,74]. Furthermore,
Murray et al. proposed guidelines and nomenclature for macrophage
activation and polarization [75]. Therefore, it could now be helpful to
have a development of standardized selection methods for collecting
the patients' samples and find ways of how to choose the therapies for
evaluating M1 and M2 in RA.
In animal models, there are various options that simulate human RA
[76] but the problem with having several models is that it could create
a limitation in producing results which are in contrast with each other.
In fact, this would likely happen due to different mouse strains, gen-
omes and different technical methods being used despite the attempts
to develop conditions as similar as possible to the alteration caused by
human RA.
For example, we found that K/B×N serum-transfer mice develop
Ly6C− monocytes which determine the infiltration in synovial tissue,
polarized as pro-inflammatory macrophages that can differentiate in
anti-inflammatory macrophage to resolve the inflammatory burden
[25].
However, in the AIA model, Ly6C+ drives the inflammation [58],
and, in this line, it is the ly6C+/(CCR)-2+ cells that control the auto-
immune tissue alterations in the CIA model of RA [77]. These con-
flicting results in differing models of animal arthritis suggest that ex-
trapolation to human RA is still premature and misleading.
Another related limitation is due to the fact that there is no one
particular standardization method to choose from among the better
considered techniques in order to evaluate macrophages taken from
synovial tissue and blood. Furthermore, the precise definition of RA
immuno-pathology (in particular, for the definition of macrophage
activity) needs markers, protein, and gene standardization methods so
as to produce reliable results. It is a known fact that laboratories around
the world all too often use different panels of macrophage identification
markers for both the blood and the synovial tissue [17,22,37].
In fact, comparing the different search methods, we could deduce
how the classical division of M1 and M2 macrophages, by itself cannot
help us to fully understand the analyzed population, and it should be
supported by more precise techniques that truly evaluate a more ac-
curate and in-depth the result [17].
To confirm this, an unexpected population with a membrane marker
of anti-inflammatory M2 macrophages (i.e. CD163+) contrarily ex-
pressed functional pro-inflammatory markers at mRNA and protein
levels. Furthermore, the stimulation of macrophages with the TLR2
receptor antagonist did change the membrane markers, but the genes
Fig. 2. Schematic representation of M1/M2 macrophages distribution in synovial tissue's layers [17,22].
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and proteins constantly showed a pro-inflammatory profile [22,64].
Thus, there are still several unanswered questions:
Are membrane markers the best method to evaluate and define
macrophage populations?
Is it still useful to use the classification based on markers for M1 and
M2 macrophages? [78].
In relation to the tissue where the macrophages are extracted, does
the function change?
In fact, the work of Ambarus et al. [17] described that, in synovial
tissue, the cellular layer (intima) presented a more defined cluster of
macrophage cells (MΦIL-10 markers colocalized with CD68+) compared
to the vascular/fibrous synovial layer where cells seems more immature
(MΦIFN-γ/MΦIL-4 & MΦIL-10). Perhaps this is due to the proximity of
blood vessels as this could create a higher level of cellular turnover.
Taking this into account, we could suppose that the particular tissue
environment (e.g. chemokines, cytokines produced by T cells, and FLS)
possibly defines the plasticity of macrophages [79,80].
This hypothesis is supported by the proposal of Mosser et al., for
which it would seem to be wiser to modify the nomenclature of the
macrophages, changing the classical membrane marker nomenclature,
and using a classification characterized on the fundamental macro-
phage function [78].
In this regard, the authors have proposed three functional classes for
macrophages namely: the host defense, wound healing, and immune
regulation. They explained that this classification method could be
more helpful in illustrating how these cells can evolve, allowing sci-
entists to more accurately identify the different macrophage levels of
activation [78].
Thus, to better understand the milieu which induces the polariza-
tion towards the pro-inflammatory or the anti-inflammatory state, after
the comprehensive overview of the literature, we have summarized the
most important molecules that seem to drive the M1/M2 macrophage
response in the RA disease.
Among anti-inflammatory molecules, TSPO seems negatively cor-
related with the progression of the disease [33]; (SIRT)-1, when acti-
vated can up-regulate the M2 macrophage transcript (human results
compared with that of mice) [34] and (SIRT)-6 correlates negatively
with systemic IL-6, and the in vivo (SIRT)-6 deficiency experiment
confirms that it is negatively associated with the M1 response [38].
The action of (SIRT)-1 is similar to the action of ET-1 which was
found to be involved in the expression of M2 markers (CD204, CD206,
CD163, IL-10 and (CCL)-22) and in the production of TGFβ1 [81].
In addition, 11β-HSD promotes the activation of glucocorticoids
(endogenous or exogenous), and shows anti-inflammatory properties in
a knock-out experiment [53]. Confirmation of the same results were for
IL-10 in Mice KO which had an aggressive production of M1 macro-
phages. Moreover, SEM3A, which has an axonal activity, can promote
the switch from M1 to M2 macrophages [37].
In regards to regulating molecules, surprisingly two μRNAs are as-
sociated with the development of the anti-inflammatory response,
namely, miR-125a-5p and miR-146a [39,40].
Conversely, Bae et al. found that both PB, synovial tissue and sy-
novial fluid miR-146a levels are elevated in patients with RA, and that
PB miR-146a levels correlate with clinical ESR values. They propose
that miR-146a concentration plays a significant part in the proin-
flammatory process in RA [82]. Furthermore, Moran-Moguel et al.
study proposed miRNA125a-5p as a potential biomarker to identify RA
patients, and categorized miRNA146a, with its associated properties,
with inflammatory macrophages in synovial tissue [83].
On the other hand, among the pro-inflammatory molecules, Activin-
a [22] and two transcription factors in downstream activity of IFN-γ,
namely, (IRF)-4 and (IRF)-5 [57]; (human and mouse) seem to be
correlated with the development of the disease, with (IRF)-5 being
more expressed in M1 than M2 macrophages [23].
In mouse cardiac (macrophage) nanotherapy, the use of the silen-
cing siRNA for (IRF)-5 has also been tested, and it produced a relevant
reduction of M1 macrophage as well as being seen to facilitate the re-
solution of the inflammatory reaction [57,84].
On the contrary, Kang et al. showed new and complex ways on how
IFN-γ may block the expression of M2 genes and favor the pro-in-
flammatory expression ones [42].
Furthermore, among the exogenous molecules/drugs approved for
RA treatment, bDMARDs were tested for the modulation of macrophage
polarization; only ETA, and ADA, both anti-TNF-α agents, have induced
the polarization of macrophage towards alternative anti-inflammatory
features by modulating the polarization of macrophages, both on the
activation of surface markers and on the expression of mRNA and cy-
tokines characterizing M2 [46].
In addition, among the bDMARDs, of particular interest is the fusion
protein CTLA-4-Ig (abatacept) which blocks the interaction between
CD80/86 and CD28 on T cells and mediates immunosuppressive ac-
tivities. However, data generated from studies about this drug and
macrophages' polarization to date is very little.
CTLA-4-Ig modulates the production of pro-inflammatory cytokines
(such as IL-6, IL-1β, TNF-α), both extracellular and cytoplasmic; also by
down-regulating the same pro-inflammatory transcript (mRNA)
[85–87]. In addition, abatacept can exert its function on different cells
inside the inflammatory milieu [88,89]. Nevertheless, reliable data on
abatacept activity to induce a shift from M1 pro-inflammatory to M2
anti-inflammatory macrophages needs to be further investigated.
Apart from bDMARDs, we found different fused macromolecules
(nanoparticle or micelles mixtures) or novel specific antagonists (all
tested in animal models) which can block the pro-inflammatory M1 or
can polarize the macrophages to the anti-inflammatory M2 response
[51,60–66,68–70,90–92].
Therefore, the future direction of nanomedicines in RA and con-
tinued research of new potential molecules might well improve the
negative patients' response, by reducing toxicity and increasing ther-
apeutic efficacy [93].
5. Conclusions
Present systematic review indicates that in blood and, more speci-
fically, in the synovial tissue of RA patients (and animal models), there
is a macrophage disequilibrium with M1 and M2 markers both present
on the surfaces of the cells.
In fact, the specific surface-cell markers seem to not always be co-
herent with the functional status of these cells (with pro or anti-in-
flammatory activity). Moreover, markers at a mRNA and protein (cy-
tokine) level show a phenotype dissociated from what should be
expected from surface-cell markers (M1 or M2).
In regards to this point, it is most important to highlight that the
role of the endogenous environmental factors, related to the circadian
rhythms of the immune-inflammatory reaction, and the related hor-
monal and cytokine changes, deeply influence cell distribution and
reactivity in the body [94–98].
Noteworthy, the production of inflammatory cytokines by resident
and activated synovial cells, could strongly modulate the plasticity of
macrophages to assume the most recent polarizing condition in-
dependent of their previous polarization state [79,80].
To conclude, we can suggest that more detailed investigations on
M1 and M2 macrophage functions are needed, as well as on their
modulation in RA, as this is essential not only for a better understanding
of the patho-physiological and clinical features of the disease, but also
to ensure a better therapeutic management of patients [88].
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